Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 6,854 shares at $21.43 ($147K) on 2024-08-01, disclosed to the SEC on 2024-08-01.
Scheduled sale ($147k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.43 | 3,377 | $72K | 49.2% |
| 2 | $21.43 | 3,377 | $72K | 49.2% |
| 3 | $22.22 | 100 | $2K | 1.5% |
| Total | $21.44 avg | 6,854 | $147K | 100% |
| Filing → |
| NRIX | SELL | 2026-05-05 | $233K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |